Status:

RECRUITING

Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

Lead Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions:

Diabetic Nephropathy

Diabetes Mellitus

Eligibility:

All Genders

18-99 years

Brief Summary

The Family Investigation of Nephropathy and Diabetes (FIND) is a multicenter study designed to identify genetic determinants of diabetic kidney disease. FIND will be conducted in eleven centers and in...

Detailed Description

The Family Investigation of Nephropathy and Diabetes (FIND) is a multicenter study designed to identify genetic determinants of diabetic kidney disease. FIND is conducted in eleven centers and in many...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Index Cases:
  • Individuals with diabetes and diabetic nephropathy who are at least 18 years of age.
  • Potential index cases must have at least one sibling, or both parents available as potential study participants.
  • Potential index cases must also have diabetic nephropathy. An index case must have nephropathy that is more severe than microalbuminuria. An index case must meet one of the following criteria:
  • Biopsy proven diabetic nephropathy (by medical record review):
  • Nodular and/or diffuse increases in the mesangial matrix accumulation; and
  • Thickened glomerular basement membranes and/or arteriolar hyalinization; and
  • Absence of mesangial immunoglobulin or paraprotein deposits by immunoflorecscence microscopy, absence of amyloid deposits by Congo Red staining or electron microscopy, absence of electron dense deposits within the glomerular basement membrane or glomerular capillary subendothelial space; and
  • Overt proteinuria, defined as ACR greater than or equal to 300 mg/g, urinary protein creatinine ratio greater than or equal to 0.5 g/g, urinary albumin excretion greater than or equal to 300 mg/24 hr, or urinary protein excretion greater than or equal to 0.5 g/24 hr.
  • ESRD (including transplant) from presumed diabetic nephropathy:
  • Diabetes present for at least 5 years prior to the initiation of replacement therapy and retinopathy at any time;
  • or Diabetes present for at least 5 years prior to the initiation of replacement therapy and either greater than or equal to 3 gm protein/24 hours, or a urine protein (mg)/creatinine (mg) greater than or equal to 3.0 or urinary ACR greater than or equal to 3000 mg/g or urinary albumin excretion greater than or equal to 3000 mg/24 hours (historical data acceptable);
  • or retinopathy and either greater than or equal to 3 gm protein/24 hours, or a urine protein (mg)/creatinine (mg) greater than 3.0 or urinary ACR greater than or equal to 3000 mg/g or urinary albumin excretion greater than 3000 mg/24 hours (historical data acceptable).
  • Patient with presumed diabetic nephropathy but not ESRD:
  • Patient has diabetic retinopathy and either greater than or equal to 1 gram proteinuria/24 hours or a urine protein (mg)/creatinine (mg) greater than or equal to 1.0 or urinary ACR greater than or equal to 1000 mg/g or urinary albumin excretion greater than or equal to 1000 mg/24 hours (historical data acceptable);
  • or first detection of either greater than or equal to 3 gram protein/24 hours or a urine protein (mg)/creatinine (mg) greater than or equal to 3.0 gram or urinary ACR greater than or equal to 3000 mg/g or urinary albumin excretion greater than or equal to 3000 mg/24 hours at DM duration greater than or equal to 10 years (historical data acceptable).
  • Recruitment of Family Members:
  • Any available parent or sibling who is at least 18 years of age will be recruited as a potential participant and will use the same criteria as above.
  • DNA for individuals in informative families will be submitted to the genotyping laboratory. An informative family is defined as one for which DNA specimens are available for the following individuals:
  • The index case and both parents, or
  • The index case and at least one other affected sibling who has diabetes and renal disease, or
  • The index case and at least one unaffected sibling, defined as an individual who has had diabetes for at least 10 years and who has no renal disease (based on evidence obtained from the medical record and from the FIND examination.

Exclusion

    Key Trial Info

    Start Date :

    March 7 2001

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    100000 Patients enrolled

    Trial Details

    Trial ID

    NCT00342927

    Start Date

    March 7 2001

    Last Update

    December 24 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    NIDDK, Phoenix

    Phoenix, Arizona, United States, 85014